Title: The pharmacology of MSC-secretome in musculoskeletal diseases

Abstract:

The prevalent incidences of musculoskeletal (MSK) pathologies demand for alternative biological approaches to be considered for relieving the substantial burden on health. Owing to their multidisciplinary actions and tremendous therapeutic effects, mesenchymal stem cells (MSCs)-based therapies represent the most promising therapeutics for regenerative medicine. The cocktail of factors secreted by MSCs, the secretome, has considerable benefits for the treatment of MSK pathologies in a cell-free system. The secretome of both adult and fetal MSCs has demonstrated enormous angiogenic and trophic effects necessary for tissue regeneration. Human MSCs share some of the proteins in their secretome that have regenerative potential promoting angiogenesis, epithelial mesenchymal transition and extracellular matrix organization.  The experimental studies have encouraging results but clinical translation into human studies is still in infancy. However, the wide scale clinical transplantation requires a detailed understanding of their mode of action, quality control and assessment of isolation and manufacturing protocols. As a combined approach, regenerative pharmacology exists at the interface between pharmacological science and regenerative medicine. The central goal is to incorporate pharmacological principles to enhance tissue regeneration. The understanding of pharmacology is essential to identify and resolve the issues associated with the clinical potential of MSC secretome-based therapies for the treatment of MSK diseases.

Biography:

She is a researcher, passionate for decoding the molecular mechanisms of human diseases to fulfill the unmet clinical needs. She enjoy devising new solutions and ideas to improve human health. Her current role is to understand the secretome of mesenchymal stem cells for the treatment of musculoskeletal pathologies.